Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
NETRIS Pharma logo — company profile

NETRIS Pharma

Founded 2008 France France 19 employees Series A Total: $13.70M Biotechnology, Health Care +2

General Information

Company Name NETRIS Pharma
Founded Year 2008
Location France France
Employees 19
Industries Biotechnology, Health Care, Life Sciences +1
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with NETRIS Pharma. To contact NETRIS Pharma, visit netrispharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does NETRIS Pharma compare?

A PDF of NETRIS Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting NETRIS Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About NETRIS Pharma

NETRIS Pharma is a biotechnology company based in France, focusing on the development of innovative cancer-fighting therapies. Established in 2008, the company has garnered attention due to its unique integration within the renowned Léon Bérard Cancer Center in Lyon, France. Their research is driven by a distinguished group's identification of cellular mechanisms, setting them apart in the biotechnology, health care, life sciences, and pharmaceutical industries.

The company's recent progress includes securing a significant €7.50M Series A investment from the European Innovation Council on December 19, 2023. This funding not only underscores investor confidence but also highlights the potential of NETRIS Pharma's endeavors in revolutionizing cancer treatment and care.

Business keywords: cancer research, pharmaceutical industry, therapeutic molecules, drug development, cellular mechanisms, Léon Bérard Cancer Center, dependence receptors, tumor development, in vitro research, in vivo research, preclinical practices, breast cancer treatment, lung cancer treatment, glioblastoma treatment

Services & Products

Development of first-in-class therapeutics targeting Netrin-1 to overcome resistance in oncology

Target Customers

Patients with cancer medical professionals research institutions

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series A €7.50M 1
European Innovation Council
European Innovation Council
19 Dec 2023
Grant $1.20M -
19 Jan 2023
Grant €2.50M 1
European Innovation Council
European Innovation Council
06 Oct 2021
Grant €2.50M 1
European Innovation Council
European Innovation Council
06 Oct 2021

NETRIS Pharma Alternatives & Competitors

View All Alternatives
NETRIS Pharma vs
XenTech
XenTech France

Premium quality preclinical oncology CRO, pioneering the PDX technology for more than 16 years.

Seed
36 employees
Biotechnology, Health Care
NETRIS Pharma vs
Semafore Pharmaceuticals
Semafore Pharmaceuticals

Pioneering the future of cancer treatment with innovative PI3K inhibitors.

Series B
Biotechnology, Health Care
NETRIS Pharma vs
Nilogen Oncosystems
Nilogen Oncosystems United States

We analyze cancer drug responses using fresh patient tumor tissue with intact tumor microenvironment...

17 employees
Biotechnology, Health Care
View all alternatives

FAQ About NETRIS Pharma

Our collaborators and partners are driven by a desire to contribute to the development of new ways of fighting cancer. The therapies developed by NETRIS Pharma are based on cellular mechanisms identified by a world-renowned research group. Located in Léon Bérard Cancer Center (Lyon, France), NETRIS...
NETRIS Pharma was founded in 2008.
NETRIS Pharma is headquartered in France.
NETRIS Pharma operates in Biotechnology, Health Care, Life Sciences and Pharmaceutical. Its work centres on cancer research, pharmaceutical industry, therapeutic molecules and drug development. Its customers include Patients with cancer, medical professionals and research institutions.
NETRIS Pharma has approximately 19 employees.
NETRIS Pharma has completed 4 funding rounds, raising a total of $13.70M. The latest funding stage is Series A.
NETRIS Pharma offers: Development of first-in-class therapeutics targeting Netrin-1 to overcome resistance in oncology.
Top alternatives and competitors to NETRIS Pharma include XenTech, Semafore Pharmaceuticals, Nilogen Oncosystems, Nanoligent, Nirogy Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NETRIS Pharma and XenTech are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for NETRIS Pharma, https://bouncewatch.com/company/netris-pharma, updated 11 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes